Compare Deere & Company (DE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Incyte Corporation — how do they compare? Deere & Company trades at $653.61 (market cap $175.95B), while Incyte Corporation trades at $112.97 (market cap $22.85B). The key difference: Deere & Company is far larger — about 7.7× Incyte Corporation's market cap, and Deere & Company pays a 0.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Incyte Corporation for 33 Days on average.
| DE | INCY | |
|---|---|---|
Market Cap | $175.95B | $22.85B |
Volume | 1,387,231 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $709.48 | $129.93 |
52-Week Low | $439.11 | $83.80 |
Typical Hold Time | 75 Days | 33 Days |
Enterprise Value | $229.85B | $18.35B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $656.87, down 3.8% on the day, showing near-term weakness despite strong earnings beats in recent quarters. The stock maintains a bullish analyst consensus with a $731.20 price target, representing 11% upside potential. Recent financial performance shows declining revenue from $60.2B in 2023 to $44.7B in 2025, though the company continues generating robust operating cash flow exceeding $7B annually. Technical indicators suggest bearish momentum with the stock trading below key resistance levels.
Deere presents a mixed investment case with attractive valuation upside but faces cyclical headwinds in agricultural equipment demand. The company's AI initiatives and dividend payments provide stability, while declining profit margins and elevated debt levels warrant caution. Wall Street remains optimistic with 43% buy ratings, though technical weakness suggests potential near-term pressure before fundamental strength prevails.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
